Rodolfo Bordoni

2.2k total citations · 1 hit paper
51 papers, 1.6k citations indexed

About

Rodolfo Bordoni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Rodolfo Bordoni has authored 51 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Rodolfo Bordoni's work include Lung Cancer Treatments and Mutations (19 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Lymphoma Diagnosis and Treatment (13 papers). Rodolfo Bordoni is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Lymphoma Diagnosis and Treatment (13 papers). Rodolfo Bordoni collaborates with scholars based in United States, France and Italy. Rodolfo Bordoni's co-authors include Jerome H. Goldschmidt, James R. Berenson, Allan Lipton, R. Bell, Michael J. Kovacs, Alan Lichtenstein, Meletios Α. Dimopoulos, Saby George, Oscar Ballester and Alan Keller and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Rodolfo Bordoni

51 papers receiving 1.6k citations

Hit Papers

Atezolizumab Plus Chemotherapy for First-Line Treatment o... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
    2020 290 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rodolfo Bordoni United States 16 1.3k 696 286 255 188 51 1.6k
M. Luisa Paccagnella United States 13 857 0.6× 275 0.4× 283 1.0× 439 1.7× 152 0.8× 22 1.7k
Oliver Rosen United States 10 689 0.5× 412 0.6× 221 0.8× 104 0.4× 94 0.5× 19 1.3k
Xiaonan Hong China 20 1.0k 0.8× 416 0.6× 930 3.3× 90 0.4× 106 0.6× 71 1.7k
B. Audhuy France 20 986 0.7× 316 0.5× 492 1.7× 432 1.7× 88 0.5× 48 1.9k
Thomas Melchardt Austria 23 559 0.4× 226 0.3× 396 1.4× 247 1.0× 89 0.5× 93 1.4k
Rodrigo Ruiz‐Soto United States 16 438 0.3× 544 0.8× 215 0.8× 63 0.2× 178 0.9× 61 1.3k
Marc André France 8 439 0.3× 436 0.6× 435 1.5× 75 0.3× 132 0.7× 19 1.0k
Robert C. Hermann United States 15 1.0k 0.8× 868 1.2× 449 1.6× 45 0.2× 139 0.7× 38 1.8k
Lucia Nogová Germany 24 683 0.5× 642 0.9× 698 2.4× 62 0.2× 205 1.1× 86 1.5k
Nushmia Z. Khokhar United States 15 898 0.7× 569 0.8× 179 0.6× 478 1.9× 72 0.4× 29 1.4k

Countries citing papers authored by Rodolfo Bordoni

Since Specialization
Citations

This map shows the geographic impact of Rodolfo Bordoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rodolfo Bordoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rodolfo Bordoni more than expected).

Fields of papers citing papers by Rodolfo Bordoni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rodolfo Bordoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rodolfo Bordoni. The network helps show where Rodolfo Bordoni may publish in the future.

Co-authorship network of co-authors of Rodolfo Bordoni

This figure shows the co-authorship network connecting the top 25 collaborators of Rodolfo Bordoni. A scholar is included among the top collaborators of Rodolfo Bordoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rodolfo Bordoni. Rodolfo Bordoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Friedberg, Jonathan W., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2023). Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 143(9). 786–795. 14 indexed citations
2.
Yasenchak, Christopher A., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2023). Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E). Blood. 142(Supplement 1). 4435–4435. 1 indexed citations
3.
Zeidan, Amer M., Rachel J. Cook, Rodolfo Bordoni, et al.. (2022). A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia. 22(7). 523–534. 10 indexed citations
4.
Peled, Nir, Delvys Rodríguez‐Abreu, Rodolfo Bordoni, et al.. (2021). 114TiP KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC). Annals of Oncology. 32. S1425–S1425. 2 indexed citations
5.
Nishio, Makoto, Fabrice Barlési, Howard West, et al.. (2020). Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.. Journal of Thoracic Oncology. 7 indexed citations
6.
NISHIO, MAKI, Fabrice Barlési, S. Ball, et al.. (2020). 375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC. Annals of Oncology. 31. S1386–S1387. 9 indexed citations
7.
Nishio, Makoto, Fabrice Barlési, Howard West, et al.. (2020). Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. Journal of Thoracic Oncology. 16(4). 653–664. 290 indexed citations breakdown →
8.
Schrock, Alexa B., Dean C. Pavlick, Samuel J. Klempner, et al.. (2018). Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research. 24(8). 1881–1890. 54 indexed citations
9.
Papadimitrakopoulou, Vassiliki A., Manuel Cobo, Rodolfo Bordoni, et al.. (2018). OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S332–S333. 102 indexed citations
10.
Pawel, Joachim von, Rodolfo Bordoni, Miyako Satouchi, et al.. (2018). Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. European Journal of Cancer. 107. 124–132. 79 indexed citations
11.
Cortinovis, Diego, Joachim von Pawel, K. Syrigos, et al.. (2017). Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK. Annals of Oncology. 28. v468–v468. 4 indexed citations
12.
Pawel, Joachim von, K. Syrigos, Julien Mazières, et al.. (2017). Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Annals of Oncology. 28. v469–v469. 28 indexed citations
13.
14.
Hart, Lowell L., Patrick J. Roberts, Renata Ferrarotto, et al.. (2017). P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results. Journal of Thoracic Oncology. 12(1). S696–S696. 1 indexed citations
15.
Jones, Benjamin, et al.. (2016). Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients. Cancer Chemotherapy and Pharmacology. 78(3). 509–515. 4 indexed citations
16.
Forero‐Torres, Andres, Beata Holkova, Jerome H. Goldschmidt, et al.. (2015). Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 126(26). 2798–2804. 95 indexed citations
17.
Yasenchak, Christopher A., Andres Forero‐Torres, Rodolfo Bordoni, et al.. (2015). Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study. Blood. 126(23). 587–587. 12 indexed citations
18.
Allendorf, Daniel J., Rodolfo Bordoni, Stefan C. Grant, et al.. (2015). Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC). Cancer Chemotherapy and Pharmacology. 76(5). 949–955. 1 indexed citations
19.
Bordoni, Rodolfo, Bruce A. Feinberg, James Gilmore, et al.. (2011). Hematologic Outcomes of Myelodysplastic Syndromes Treatment With Hypomethylating Agents in Community Practice. Clinical Lymphoma Myeloma & Leukemia. 11(4). 350–354. 6 indexed citations
20.
Socinski, Mark A., Mansoor N. Saleh, David Trent, et al.. (2009). A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals of Oncology. 20(6). 1068–1073. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Luisa Paccagnella Breakdown of academic impact, for papers by Oliver Rosen Breakdown of academic impact, for papers by Xiaonan Hong Breakdown of academic impact, for papers by B. Audhuy Breakdown of academic impact, for papers by Thomas Melchardt Breakdown of academic impact, for papers by Rodrigo Ruiz‐Soto Breakdown of academic impact, for papers by Marc André Breakdown of academic impact, for papers by Robert C. Hermann Breakdown of academic impact, for papers by Lucia Nogová Breakdown of academic impact, for papers by Nushmia Z. Khokhar
Rankless by CCL
2026